Cutaneous complications of insulin therapy. A drug-induced condition on the decline;Complications cutanées de l'insulinothérapie un problème iatrogène sur le déclin

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 564-565

  Pierard Franchimont C ^a   Hermanns Le T ^a   Scheen, A J ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Diabetes; Drug reaction; Hypodermis; Infection; Insulin

Indexed keywords

INSULIN;

DIABETES MELLITUS; DRUG HYPERSENSITIVITY; HUMAN; INSULIN TREATMENT; LIPOATROPHY; LIPOHYPERTROPHY; REVIEW; SKIN ABSCESS;

ABSCESS; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SKIN DISEASES;

EID: 21744445946     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Scherbaum WA. - Insulin therapy in Europe. Diabetes Metab Res Rev, 2002, 18, S50-S56.
2. Richardson T, Kerr D. - Skin-related complications of insulin therapy, Epidemiology and emerging management strategies. Am J Clin Dermatol, 2003, 4, 661-667.
3. McNally PG, Jowett NI, Kurinczuk JJ, et al. - Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J, 1988, 64, 850-853.
4. Murao S, Hirata K, Ishida T, et al. - Lipoatrophy induced by recombinant human insulin injection. Intern Med, 1998, 37, 1031-1033.
5. Mu L, Goldman JM. - Human recombinant DNA insulin-induced lipoatrophy in a patient with type 2 diabetes mellitus. Endocr Pract, 2000, 6, 151-152.
6. Griffin ME, Feder A, Tamborlane WV. - Lipoatrophy associated with lispro insulin in insulin pump therapy. Diabetes Care, 2001, 24, 174.
7. Raile K, Noelle V, Landgraf R, et al. - Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes, 2001, 109, 393-396.
8. Hauner H, Stockamp B, Haaster B. - Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes, 1996, 104, 106-110.
9. Turner BC, Heijlesen OK, Kerr D, et al. - Impaired absorption and omission of insulin: a novel method of detection using the diabetes advisory system computer model. Diabetes Technol Ther, 2001, 3, 99-109.
10. Yasuda H, Nagata M, Moriyama H, et al. - Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care, 2001, 24, 2008-2009.
11. Lapière ChM, Piérard GE, Hermanns JF, et al. - Unusual extensive granulomatosis after long term use of plastic syringes for insulin injections. Dermatologica, 1982, 165, 559-567.
12. DeShazo RD, Boehm TM, Kumar D, et al. - Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histology. J Allergy Clin Immunol, 1982, 69, 229-237.
13. Bollinger ME, Hamilton RG, Wood RA. - Protamine allergy as a complication of insulin hypersensitivity; a case report. J Allergy Clin Immunol, 1999, 194, 462-465.
14. Lee AY, Chey WY, Choi J, et al. - Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol, 2002, 82, 114-117.
15. Takata H, Kumon Y, Osaki F, et al. - The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care, 2003, 26, 253-254.
16. Guinn TS, Bailey GJ, Mecklenberg RS. - Factors related to discontinuation of subcutaneous insulin infusion therapy. Diabetes Care, 1988, 11, 46-51.
17. Mecklenberg RS, Benson EA, Benson JrJW, et al. - Acute complications associated with insulin pump therapy: report of experience with 161 patients. JAMA 1984, 252, 3265-3269.
18. Chantelau E, Spraul M, Muhlhauser I, et al. - Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for Type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia, 1989, 32, 421-426.
19. Wickline CL, Cornitus TG, Butler T. - Cellulitis caused by Rhizomucor pusillus in a diabetic patient receiving continuous insulin pump therapy. Southern Med J, 1989, 82, 1432-1434.
20. Quatresooz P, Arrese JE, Piérard GE. - Synopsis des dermatomycoses invasives chez l'immunodéprimé. Rev Med Liege, 2003, 58, 690-694.
21. Anderson JA, Adkinson NF. - Allergic reactions to drugs and biologic agents. JAMA, 1987, 258, 2891-2899.
22. Hermanns-Lê T, Hermanns JF, Piérard GE. - Juvenile acanthosis nigricans and insulin resistance. Fed Dermatol, 2002, 19, 12-14.
23. Hermanns-Lê T, Scheen A, Piérard GE. - Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol, 2004, 5, 199-203.
24. Dische FE, Wernstedt C, Westermark GT, et al. - Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia, 1988, 31, 158-161.
25. Swift B, Hawkins PN, Richards C, et al. - Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med, 2002, 19, 881-882.
26. Wheatley T, Edwards OM. - Insulin cedema and its clinical significance: metabolic studies in three cases. Diabet Med, 1985, 2, 400-404.